At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Active-Controlled, Double-Blind Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants Given With Routine Pediatric Vaccinations in the United Kingdom
In Brief
A Phase 3 clinical trial evaluating 13-valent Pneumococcal Conjugate Vaccine, 7vPnC, and 3 other interventions for Vaccines, Pneumococcal. Completed, enrolled 286 participants across 11 sites.
Detailed Summary
The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when given concomitantly with routine paediatric vaccines in the United Kingdom.
Study Details
Timeline
Interventions
Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age